Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Thoracic malignancies 1

1308 - Prevalence of NTRK gene fusions in a large cohort of Japanese patients with lung cancer (415O)

Date

17 Nov 2017

Session

Thoracic malignancies 1

Topics

Translational Research;  Non-Small Cell Lung Cancer

Presenters

Atsushi Nakamura

Citation

Annals of Oncology (2017) 28 (suppl_10): x124-x143. 10.1093/annonc/mdx671

Authors

A. Nakamura1, H. UDAGAWA2, S. Matsumoto2, S. Sugawara3, M. Shingyoji4, A. Horiike5, I. Okamoto6, T. Hida7, S. Saeki8, Y. Ohe9, D. Ogawara10, Y. Kataoka11, Y. Miyata12, H. Mitsufuji13, S. Kuyama14, R. Kanemaru15, T. Kato16, A. Hirata17, K. Yoh2, K. Goto2

Author affiliations

  • 1 Department Of Pulmonary Medicine, Sendai Kousei Hospital, 980-0873 - Sendai/JP
  • 2 Department Of Thoracic Oncology, National Cancer Center Hospital East, 277-8577 - Kashiwa/JP
  • 3 Pulmonary Medicine, Sendai Kousei Hospital, 980-0873 - Sendai/JP
  • 4 Division Of Respirology, Chiba Cancer Center, Chiba/JP
  • 5 Department Of Thoracic Medical Oncology, Cancer Institute Hospital of JFCR, 135-8550 - Tokyo/JP
  • 6 Research Institute For Diseases Of The Chest, Kyusyu University, Fukuoka/JP
  • 7 Department Of Thoracic Oncology, Aichi Cancer Center Hospital, 464-8681 - Nagoya/JP
  • 8 Department Of Respiratory Medicine, Kumamoto University Hospital, Kumamoto/JP
  • 9 Department Of Thoracic Oncology, National Cancer Center Hospital, 104-0045 - Tokyo/JP
  • 10 Department Of Respiratory Medicine, Sasebo City General Hospital, Sasebo/JP
  • 11 Respiratory Mesicine, Hyogo Prefectural Amagasaki Hospital, 660-0828 - Amagasaki/JP
  • 12 Department Of Surgical Oncology, Hiroshima University, 734-8551 - Hiroshima/JP
  • 13 Department Of Respiratory Medicine, Kitasato University School of Medicine, Sagamihara/JP
  • 14 Department Of Respiratory Medicine, NHO Iwakuni Clinical Center, Iwakuni/JP
  • 15 Department Of Respiratory Medicine, Juntendo University Graduate School of Medicine, Tokyo/JP
  • 16 Department Of Thoracic Oncology, Kanagawa Cancer Center, Yokohama/JP
  • 17 Department Of Respiratory Medicine, Kyorin University Hospital, Tokyo/JP
More

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1308

Background

Several actionable gene alterations, such as EGFR and KRAS mutations, for lung cancer are different in frequency between Caucasian and East Asian. NTRK fusions have been recently identified as a therapeutic target in a rare fraction of Caucasian patients with lung adenocarcinoma (3.3%). However, their frequency in East Asian has not yet been examined.

Methods

A nationwide lung cancer genomic screening project in Japan (LC-SCRUM-Japan) was initiated from February 2013, and a total of 4118 lung cancer patients have been enrolled as of April 2017. A total of 2668 patients with lung cancer (non-squamous/squamous/small=2088/275/305) were screened by using a next generation sequencing platform, Oncomine™ Focus Assay (OFA) for detecting NTRK1/2/3 fusions or Oncomine™ Comprehensive Assay (OCA) for detecting NTRK1/3 fusions.

Results

Only one patient with ETV6-NTRK3 fusion (0.04%) was detected. The patient harboring ETV6-NTRK3 fusion was a 60-year-old man with a 35 pack-year smoking history, and pathologically diagnosed with adenocarcinoma. We also evaluated NTRK1 gene fusion–induced imbalances in the expression of the 5’ and 3’ regions of the transcripts using the OFA sequencing data, and there was no case with 5’/3’ expression imbalances of NTRK1 gene transcripts.

Conclusions

The frequency of NTRK fusions in Japanese patients with lung cancer is extremely rare (0.04%) compared with Caucasian.

Clinical trial identification

Legal entity responsible for the study

National Cancer Center

Funding

Taiho, Chugai, Ono, Astra Zeneka, Bristol-Myers Squibb, MSD, Astellas, Eisai, DAIICHI SANKYO, Pfizer, Kyowa Hakko Kirin, Novartis, Takeda, Eli Lilly Japan, Merck Serono, Boehringer Ingelheim, Amgen

Disclosure

T. Hida: Ignyta, Y. Ohe: HONORARIA: AstraZeneca, Chugai, Lilly, ONO, BMS, Daiichi-Sankyo, Nipponkayaku, Boehringer Ingelheim, Bayer, Pfizer, MSD, Taiho RESEARCH FUNDING: AstraZeneca, Chugai, Lilly, ONO, BMS, Kyorin, Dainippon- Sumitomo, Pfizer, Taiho, Novartis, Merck Serono, CONSULTING OR ADVISORY ROLE: AstraZeneca, Chugai, Lilly, ONO, Novartis, S. Kuyama: HONORARIA: AstraZeneca, Meiji Seika, Boehringer Ingelheim, Lilly, Chugai, ONO, MSD, K. Yoh: Dr. Yoh has received personal fees as honoraria from Chugai, Eli Lilly, AstraZeneca, Taiho, Boehringer Ingelheim, Bristol-Myers Squibb, and Ono. His institution has received research funding from Pfizer, Taiho, Eli Lilly, AstraZeneca, Bayer and Novartis. K. Goto: Corporate-sponsored research: Taiho, Chugai, Ono, Astra Zeneka, Sumitomo Dainippon, Bristol-Myers Squibb, MSD, Astellas, Eisai, DAIICHI SANKYO, Pfizer, Kyowa Hakko Kirin, Novartis, Takeda, Eli Lilly Japan, Merck Serono, OxOnc, AbbVie Stemcentrx, Ignyta, Boehringer Ingelheim

All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.